ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Two biotech firms pare staff

November 6, 2006 | APPEARED IN VOLUME 84, ISSUE 45

Critical Therapeutics is cutting 63 positions, more than half its workforce, as it focuses on commercializing the controlled-release form of zileuton for the treatment of asthma. Among the eliminated jobs are 20 in R&D and 32 in the sales and marketing of standard zileuton, sold as Zyflo. Meanwhile, QLT is eliminating about 80 jobs in response to a continued decline in sales of Visudyne, its treatment for age-related macular degeneration. QLT employed 438 people as of March 1.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment